Showing 1951-1960 of 2888 results for "".
- Hair Relaxers Linked to Uterine Cancer in Black Womenhttps://modernaesthetics.com/news/hair-relaxers-linked-to-uterine-cancer-in-black-women/2473506/Long-term use of chemical hair relaxers by postmenopausal Black women may increase risk of uterine cancer, according to a new study by researchers at Boston University’s Black Women’s Health Study (BWHS). These products contain potentially harmful ingredients, including chem
- BeautyHealth Launches New Hydrafacial School Partner Program for Student Estheticianshttps://modernaesthetics.com/news/beautyhealth-launches-new-hydrafacial-school-partner-program-for-student-estheticians/2473505/The Beauty Health Company is introducing the Hydrafacial School Partner Program to accredited esthetic schools across the U.S. Piloted first with select Paul Mitchell Schools and Aveda Institute locations, the Hydrafacial School Partner Program offers participating schools and the
- RelabotulinumtoxinA Update from Galdermahttps://modernaesthetics.com/news/relabotulinumtoxina-update-from-galderma/2473504/The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Galderma related to its pending Biologics License Application (BLA) for RelabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity
- Industry Vet Aaron Green Joins RepeatMDhttps://modernaesthetics.com/news/industry-vet-aaron-green-joins-repeatmd/2473498/Aaron Green is RepeatMD’s new Vice President of Business Development. RepeatMD is a mobile shopping platform that integrates ecommerce and fintech solutions, providing aesthetic and wellness practices with a personalized shopping experience for their patients. &quo
- Will Platysma Prominence Be the Next Nod for BOTOX Cosmetic?https://modernaesthetics.com/news/will-platysma-prominence-be-the-next-nod-for-botox-cosmetic/2473497/Allergan Aesthetics’ BOTOX Cosmetic met all primary and secondary endpoints for the treatment of moderate to severe platysma prominence associated with platysma muscle activity, according to topline results from the second of three Phase 3 studies. The multicenter, randomized
- FDA Grants 510(k) Clearance to Venus the Versa Pro Systemhttps://modernaesthetics.com/news/fda-grants-510k-clearance-to-venus-the-versa-pro-system/2473495/The U.S. Food and Drug Administration has granted marketing clearance to Venus Concept Inc.’s Venus Versa Pro System. Venus Versa is customizable and upgradable and supports 10 optional applicators which utilize Venus Concept’s (MP)2, IPL and NanoFractional RF tec
- Cutera Introduces Secret DUOhttps://modernaesthetics.com/news/cutera-introduces-secret-duo/2473490/Cutera, Inc. is launching Secret DUO, a skin resurfacing and revitalization platform that utilizes dual non-ablative fractional technologies. Each modality can be used individually or in combination to target a wide range of aesthetic indications. Secret DUO is equipped
- Cutera, Inc. Appoints Jeff Jones as Chief Operating Officerhttps://modernaesthetics.com/news/cutera-inc-appoints-jeff-jones-as-chief-operating-officer/2473482/Jeff Jones is Cutera, Inc.’s new Chief Operating Officer, effective August 28, 2023. Mr. Jones will report directly to Taylor Harris, Cutera’s Chief Executive Officer, and will be responsible for end-to-end operations, including manufacturing, quality, supply chain, fi
- Dr. Ashley Brissette Is Clinique’s First Guiding Ophthalmologisthttps://modernaesthetics.com/news/nyc-ophthalmologist-dr-ashley-brissette-is-cliniques-first-guiding-ophthalmologist/2473481/NYC-based ophthalmologist Ashley Brissette, MD, MSc, FRCSC, is Clinique’s first guiding ophthalmologist. In the newly created role, Dr. Brissette will help educate consumers on the importance of eye safety, help guide the development of new products, and contribute to C
- Delnova Demonstrates Proof of Concept for ReViVoxhttps://modernaesthetics.com/news/delnova-demonstrates-proof-of-concept-for-revivox/2473478/Delnova’s ReViVox showed reversal or muscle paralysis or weakness in a small cohort of healthy subjects. ReViVox is being developed to resolve side effects that may result from botulinum neurotoxin treatments. In the proof-of-concept study, volunteer subj